Johnson Pharmacare (532154) Q2 25/26 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and half year ended September 30, 2025.

• Financial results were reviewed by the Audit Committee and received a limited review from statutory auditors.

Financial highlights

• Total income from operations for the quarter and half year ended September 30, 2025, was nil.

• Net loss for the quarter ended September 30, 2025, was ₹0.34 lakhs; for the half year, net loss was ₹5.68 lakhs.

• Basic and diluted EPS for the quarter and half year were both ₹(0.00).

• Paid-up equity share capital stood at ₹5,500 lakhs as of September 30, 2025.

Key financial ratios and metrics

• Other equity as of September 30, 2025, was ₹116.91 lakhs.

• Total assets as of September 30, 2025, were ₹5,836.76 lakhs.

• Net cash flow from operating activities for the half year was ₹48.33 lakhs.

• Cash and cash equivalents at period end were ₹3.11 lakhs.